By: Donghui Qin, Yuanyuan Ren, Na Zhang, Xue Yang, Zhuo Chen, Changliang Zhao
Keywords: Unstable angina, ticagrelor, clopidogrel, angina attacks, serum inflammatory factor levels, blood lipid levels, major adverse cardiovascular and cerebrovascular events (MACCE), bleeding events, adverse reactions.
DOI : 10.36721/PJPS.2025.38.1.REG.077-082.1
Abstract: To evaluate the comparative efficacy of Ticagrelor and Clopidogrel in treating patients with coronary heart disease and unstable angina, as well as their effects on serum inflammatory factors, thereby providing a solid foundation for future clinical diagnosis and treatment. The frequency of angina attacks in the Ticagrelor group was lower than in the Clopidogrel group (P< 0.05). The duration of angina and shortness of breath were also shorter in the Ticagrelor group (P<0.05). The levels of C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-18 (IL-18), matrix metalloproteinase-9 (MMP-9), lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO), type 1 tissue plasminogen activator inhibitor (tPAI-1), homocysteine (Hcy), endothelin-1 (ET-1), tumor necrosis factor-alpha (TNF-?), platelet-derived growth factor (PDGF), brain natriuretic peptide (BNP), soluble CD40 ligand (sCD40L), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule (sLCAM-1), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triglycerides (TG), as well as the incidence of MACCE events, were all lower in the Ticagrelor group compared to the Clopidogrel group (P<0.05), while high-density lipoprotein cholesterol (HDL-C) levels and overall efficacy were higher in the Ticagrelor group (P<0.05). Ticagrelor demonstrates superior therapeutic efficacy compared to Clopidogrel in patients with coronary heart disease and unstable angina, effectively reducing serum inflammatory factor levels.
[View Complete Article]
